AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Paradigm Biopharmaceuticals Limited:
Paradigm Biopharmaceuticals Limited (ASX:PAR) is an Australian biopharmaceutical company. The company is into the R&D of therapeutic products for human use. It also focusses on repurposing pentosan polysulphate sodium to treat inflammation.
On 28 May 2019, the company stated that there was a 50% reduction in pain for almost 205 patients suffering from knee osteoarthritis, when treated with injectable pentosan polysulfate under the TGA SAS. This result depicts consistent safety and efficacy and delivers Real-World Evidence. The company had completed the production of its Phase 3 Clinical trial product and under it, patients would be treated from Q319.
PAR had previously reported major decrease in BML in sites of the body parts other than the knee using iPPS under the TGA special access scheme.
Before and after MRI (Source: Companyâs report)
PAR had also recently completed the retail component of its 1 for 8 accelerated non-renounceable entitlement offer, which raised almost $16.5 million at $1.50 per Share.
On 30 May 2019 the stock closed at A$1.460, up by 1.038% from its previous close on ASX.
Noxopharm Limited:
A clinical-stage drug development player, Noxopharm Limited (ASX: NOX) has offices in New York and Sydney. Its focus lies on the treatment of different forms of cancer. It aims to develop drugs that are built on a phenolic chemical structure. Veyondaâ is its primary pipeline product. It is a formulation of the trial anti-cancer drug called idronoxil. The pipeline has other oncology and non-oncology drug candidates.
The company recently announced that the DARRT-1 study had completed enrolment. This is NOXâs first clinical study of DARRT. It is being conducted in Australia and Georgia and is a Phase 1b 24-subject study.
The Veyondaâ process (Source: Company website)
NOX also notified that the LuPIN trial was due to be expanded to include an additional dose cohort. This was taking place in collaboration with the St Vincentâs Hospital to investigate the 177Lu-PSMA-617 in combination with Veyondaâ in men.
On 30 May 2019, the stock closed at A$0.620, marginally down by 0.8% from its previous close on ASX.
Rhinomed Limited:
Rhinomed Limited (ASX: RNO) focusses on respiratory, nasal and breathing management technologies. It is a leader in airway technology and is based in Melbourne. RNO caters to the sleep, drug delivery, sport and well-being markets, where it aims to monetise the applications of its technology portfolio. Also, RNO is the developer of Muteâ¢.
The company recently announced that new Pronto⢠- which is a dual action, rechargeable and a vapour releasing technology, have been finally registered with the Australian TGA and the US FDA as a class I medical device.
The Pronto⢠(Source: Companyâs report)
As per its Quarterly report, the companyâs revenue increases 64% up to $1.012 million. It also won the US Drug Store News âRetail Excellence Awardâ in the OTC category. The FY 19 YTD revenues were $2.4m (as reported on 29th April 2019). This exceeded the revenues of entire FY18 period.
Quarterly revenue (Source: Companyâs report)
The net cash used in operating activities amounted to $1,432k. The closing cash balance of $2.5 million depicted a net burn of $1.3 million.
On 30 May 2019, the stock closed at A$0.270, up by 3.846% from its previous close on ASX.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
